Refractory Disease

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

DESTIN, Fla. — Although the strongest predictor of malignancy in dermatomyositis is age, all adult patients should undergo cancer screening, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — Standard care treatments for multiple myeloma conferred markedly shorter survival benefits in real-world settings, study results presented at ASH Annual Meeting and Exposition showed.

Jakub Svoboda, MD, of Penn Medicine, discussed data from the ZUMA-12 study presented at the ASH Annual Meeting and Exposition.

New treatments and trial designs, particularly focused on patients with refractory disease, remain among the top unmet needs in rheumatology in 2019, according to expert opinions culled from the Advances in Target Therapies annual meeting and published in the Annals of the Rheumatic Diseases.